Millions of people with chronic kidney disease who have never been diagnosed with diabetes now have strong clinical evidence that a class of drugs originally designed to lower blood sugar can slow their kidney decline. The EMPA-KIDNEY trial, a large randomized study of the SGLT2 inhibitor empagliflozin, found that the drug reduced the combined risk of kidney disease progression or cardiovascular death across a broad population of CKD patients, including a substantial subgroup of more than 3,500 participants without diabetes. The results add to earlier findings from a separate trial of a related drug, dapagliflozin, and together they challenge the long-held assumption that these medications work primarily by controlling glucose.
Why SGLT2 inhibitors in nondiabetic kidney disease demand attention
Chronic kidney disease affects tens of millions of Americans, and for decades the standard treatments available to patients without diabetes were limited to blood pressure control and a handful of other interventions. SGLT2 inhibitors, sold under brand names like Jardiance (empagliflozin) and Farxiga (dapagliflozin), entered the market as glucose-lowering pills for type 2 diabetes. Their unexpected kidney-protective effects emerged from cardiovascular safety trials and prompted researchers to ask whether the benefit extended to people whose kidneys were failing for reasons unrelated to high blood sugar.
The answer, based on two major randomized trials, is yes. EMPA-KIDNEY was designed as a randomized, double-blind, placebo-controlled study enrolling patients across a wide range of CKD causes and severity levels, as described in the primary report. Its inclusion of a large nondiabetic subgroup was deliberate, not an afterthought. The trial’s design and baseline characteristics, including the specific CKD phenotypes enrolled and the prespecified analysis plan, were published before the main results appeared. That planning matters because it means the nondiabetic findings were not cherry-picked from a dataset after the fact.
The central hypothesis driving interest in these drugs outside of diabetes centers on kidney physiology rather than blood sugar. SGLT2 inhibitors block glucose reabsorption in the kidney’s proximal tubule, which triggers a feedback mechanism that constricts the afferent arteriole feeding each glomerulus. This reduces the pressure inside the glomerular capillaries, a force that drives progressive scarring in damaged kidneys regardless of whether diabetes caused the initial injury. The drugs also reduce albuminuria, the leakage of protein into urine that serves as both a marker and an accelerator of kidney damage. If the benefit truly stems from these pressure and filtration changes rather than from glucose control, it would explain why patients without diabetes see similar protection.
Trial evidence linking empagliflozin and dapagliflozin to kidney protection
EMPA-KIDNEY, registered as NCT03594110, recruited patients with estimated glomerular filtration rates as low as 20 mL per minute and included people with conditions such as IgA nephropathy and other non-diabetic kidney diseases. The primary outcome was a composite of kidney disease progression or death from cardiovascular causes. Empagliflozin reduced that composite risk in the overall population, and the benefit held in the nondiabetic subgroup. Extended follow-up data published in the New England Journal of Medicine confirmed that the long-term effects of empagliflozin on kidney protection persisted beyond the initial trial period, addressing concerns about whether the drug merely delayed rather than prevented decline.
Before EMPA-KIDNEY reported, the DAPA-CKD trial had already demonstrated that dapagliflozin reduced kidney failure and related outcomes in CKD patients both with and without type 2 diabetes. A prespecified subgroup analysis from DAPA-CKD explicitly compared diabetic and nondiabetic participants and found consistent benefits across both groups. That analysis was built into the trial protocol from the start, giving it stronger statistical standing than a post hoc exploration would carry.
The convergence of two independent, large-scale trials testing two different SGLT2 inhibitors and reaching the same conclusion in nondiabetic patients is significant. It suggests the kidney protection is a class effect rather than a quirk of one molecule or one patient population. The FDA recognized this evidence when it approved dapagliflozin for CKD regardless of diabetes status, a regulatory decision documented in an agency announcement covering the Farxiga label expansion. For patients and clinicians, this means that kidney-protective therapy is no longer reserved only for those whose kidney disease stems from diabetes.
Gaps in the data and what kidney patients should watch for next
Several questions remain open despite the strength of these trial results. Individual patient-level hazard ratios specifically for the nondiabetic subgroup in EMPA-KIDNEY have not been fully detailed in the public trial registry, and clinicians still want to understand whether certain causes of CKD respond better than others. For example, it is not yet clear whether people with predominantly cystic kidney diseases, severe vascular kidney damage, or advanced scarring gain the same relative benefit as those with immune-mediated conditions like IgA nephropathy.
Another uncertainty involves how early in the course of kidney disease SGLT2 inhibitors should be started in people without diabetes. EMPA-KIDNEY and DAPA-CKD enrolled patients with moderately to severely reduced kidney function, and many had significant albuminuria. Whether patients with milder disease, normal or near-normal albumin levels, or rapidly changing kidney function would see the same degree of protection remains to be tested in dedicated studies.
Safety is a further consideration. While SGLT2 inhibitors are generally well tolerated, they can increase the risk of genital infections and may cause volume depletion, especially in older adults or those taking diuretics. In nondiabetic patients, clinicians also monitor for rare events like ketoacidosis, although the risk appears low in the CKD populations studied so far. Understanding how these adverse events balance against the potential to delay dialysis or transplantation is central to future guideline recommendations.
Cost and access issues also loom large. Even with strong evidence, newer medications can be difficult for patients to obtain if insurance coverage is inconsistent or if out-of-pocket costs are high. Policymakers and payers will need to decide how to prioritize SGLT2 inhibitors within broader strategies to manage CKD, a condition that already accounts for substantial healthcare spending due to hospitalizations, dialysis, and transplant care.
For patients living with nondiabetic CKD today, the practical takeaway is that a conversation with their nephrologist or primary care clinician about SGLT2 inhibitors is warranted. Not everyone will be an appropriate candidate, and these drugs are meant to complement-not replace-established therapies such as blood pressure control with ACE inhibitors or ARBs, dietary sodium restriction, and careful management of cardiovascular risk factors. But for many, adding an SGLT2 inhibitor could meaningfully change the trajectory of kidney decline.
Future research will likely refine who benefits most, how to combine SGLT2 inhibitors with other emerging kidney-protective agents, and how long therapy should continue once patients approach end-stage kidney disease. As those answers emerge, the core message from EMPA-KIDNEY and DAPA-CKD is already reshaping practice: the kidney benefits of SGLT2 inhibition extend well beyond diabetes, and for a large group of people with chronic kidney disease, that shift in understanding may translate into more years with better-preserved kidney function.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
